Structure Therapeutics (GPCR) Income from Continuing Operations (2022 - 2026)
Quarterly Income from Continuing Operations fell 62.21% to 75968000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 26260000.0 through Mar 2026, up 80.43% year-over-year, with the annual reading at 2875000.0 for FY2025, 102.53% up from the prior year.
Structure Therapeutics' Income from Continuing Operations history spans 5 years, with the latest figure at 75968000.0 for Q1 2026.
- Income from Continuing Operations came in at 75968000.0 for Q1 2026, down from 177081000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 177081000.0 in Q4 2025 to a low of 75968000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 23862000.0 (2023), against an average of 14146823.53.
- Year-over-year, Income from Continuing Operations soared 1247.36% in 2023 and then crashed 149.4% in 2024.
- Structure Therapeutics' Income from Continuing Operations stood at 4829000.0 in 2022, then skyrocketed by 1247.36% to 55406000.0 in 2023, then plummeted by 149.4% to 27370000.0 in 2024, then skyrocketed by 746.99% to 177081000.0 in 2025, then crashed by 142.9% to 75968000.0 in 2026.
- Per Business Quant, the three most recent readings for GPCR's Income from Continuing Operations are 75968000.0 (Q1 2026), 177081000.0 (Q4 2025), and 65712000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | -75.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.97 Mn |
| Dec 31, 2025 | 177.08 Mn |
| Sep 30, 2025 | -65.71 Mn |
| Jun 30, 2025 | -61.66 Mn |
| Mar 31, 2025 | -46.83 Mn |
| Dec 31, 2024 | -27.37 Mn |
| Sep 30, 2024 | -33.98 Mn |
| Jun 30, 2024 | -26.03 Mn |
| Mar 31, 2024 | -26.04 Mn |
| Dec 31, 2023 | 55.41 Mn |
| Sep 30, 2023 | -23.86 Mn |
| Jun 30, 2023 | -23.28 Mn |
| Mar 31, 2023 | -17.98 Mn |
| Dec 31, 2022 | -4.83 Mn |
| Sep 30, 2022 | -12.42 Mn |
| Jun 30, 2022 | -13.95 Mn |
| Mar 31, 2022 | -13.08 Mn |